Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia

Br J Haematol. 2019 Oct;187(1):e20-e24. doi: 10.1111/bjh.16136. Epub 2019 Aug 8.

Rob S Sellar^{1

2}, Varun Mehra³, Thomas A Fox⁴, Andrew Grigg⁵, Austin Kulasekararaj³, Anita Sarma³, Hugues de Lavallade³, Donal McLornan^{3

6}, Kavita Raj^{3

7}, Ghulam J Mufti³, Antonio Pagliuca³, Stephen Mackinnon², Ronjon Chakraverty^{1

2

4}, Adele K Fielding^{1

2}, Ben Carpenter², Panagiotis D Kottaridis², Asim Khwaja^{1

2}, Karl S Peggs^{1

2}, Kirsty J Thomson², Emma C Morris^{2

4

7}, Victoria T Potter³

¹ Department of Haematology, UCL Cancer Institute, London, UK.
² Department of Haematology, University College London Hospitals, London, UK.
³ Department of Haematology, King's College Hospital, London, UK.
⁴ Institute of Immunity and Transplantation, University College London, London, UK.
⁵ Department of Oncology and Clinical Haematology, Austin Hospital, Melbourne, VIC, Australia.
⁶ Department of Haematology, Guys and St Thomas' Hospital, London, UK.
⁷ Department of Immunology, Royal Free Hospital, London, UK.

No abstract available

Keywords: T-cell deplete conditioning; acute myeloid leukaemia; alemtuzumab; allogeneic stem cell transplant.

Publication types